14 results about "Cell invasion" patented technology

Method for generating a porous injectable scaffold that includes providing a liquid composition of 2 phases at a temperature below 25° C., of Newtonian behavior, where the composition comprises:a liquid dispersant phase at room temperature formed by a gelatin with a low melting point, less than 15° C., functionalized with methacryloyl or methacrylamide groups; and a photoinitiator;and a dispersed phase, of microdroplets or beads in solid state, of a gelatin solution with a melting point greater than 25° C.;initiating the polymerization of the dispersing phase by light radiation; raising the temperature to 35-40° C. and allowing melting of the dispersed phase; and obtaining a porous scaffold.The formed porous scaffold and its use as a biological support for tissue regeneration / generation; as a biological matrix as a support for cells, for cell invasion; as an acellular biological matrix, a biological matrix as a mechanical support and / or a biological matrix for active components.

Proposed are antibodies specifically binding to PTK7 and a use thereof and, more particularly, PTK7 neutralizing antibodies specifically binding to PTK7 to inhibit PTK function, and a use thereof for inhibiting angiogenesis, cell growth, cell migration, and cell invasion. The human PTK7 neutralizing monoclonal antibodies have been found to independently exhibit an effective inhibitory effect on cancer cell growth, migration, invasion in esophageal squamous cell carcinoma and triple-negative breast cancer, and angiogenesis. Therefore, the human PTK7 neutralizing monoclonal antibodies can be applied to various PTK7-positive carcinomas and angiogenic diseases, and can be further developed as a targeted drug therapy for intractable cancers and angiogenic diseases to be used as a core global treatment drug for the same.

The invention relates to a compound for inhibiting osteosarcoma cell invasion and metastasis capability and application of the compound, in particular to application of a PAC channel inhibitor to preparation of a composition or a preparation, and the composition or the preparation is used for preventing and / or treating osteosarcoma. It is found for the first time that PAC channel inhibitors (such as Evans blue (EB), trypan blue (TB), aniline blue (AB), Coomassie brilliant blue (CBB), Cicago sky blue 6B (CSB), direct blue 71 (DB-71) and thiazole yellow (TY)) effectively prevent and / or treat osteosarcoma by inhibiting the activity of PAC channels.

The invention belongs to the field of medicines, and particularly relates to application of oseltamivir in a medicine for inhibiting porphyromonas gingivalis infected esophageal squamous cell carcinoma. According to the application of oseltamivir in the medicine for inhibiting the porphyromonas gingivalis infection type esophageal squamous cell carcinoma, tumor cell proliferation, cell migration and cell invasion of the porphyromonas gingivalis infection type esophageal squamous cell carcinoma can be inhibited.

The invention provides an application of FGF4 (fibroblast growth factor 4) as a drug target in treatment of enameloblastoma, relates to the technical field of biological medicines, finds a potential effect of the FGF4 in the enameloblastoma for the first time, proves an inhibition effect of the FGF4 on tumor growth, proves that the FGF4 can be used as a treatment target of the enameloblastoma, and proves that the FGF4 gene is knocked down in an enameloblastoma cell line, so that the treatment effect on the enameloblastoma is obviously improved. Cell proliferation, cell migration, cell invasion and cell colony formation can be inhibited; in an animal body, the FGF4 gene is knocked down to inhibit the growth of the enameloblastoma, which shows that the FGF4 has the effect of regulating and controlling the growth of the enameloblastoma, and the FGF4 inhibitor can inhibit the proliferation, migration, invasion and cell colony formation of an enameloblastoma cell line and inhibit the growth of the enameloblastoma. A new treatment target is provided for prevention and / or treatment of the glamoblastoma, and the application has a wide clinical application value.

This invention discloses a system for rapid detection of tumor cell invasiveness and risk level reference based on matrix remodeling fluorescence reporter assay. After staining, test cells are seeded on a matrix material formed by cell adhesion ligands and fluorescent dye-modified polyisocyanate peptides for 2D culture, or the two components are thoroughly mixed and gelled to form a 3D culture environment, resulting in a cell-induced matrix remodeling fluorescence detection system. Fluorescence images of the area surrounding the sample are acquired, and cell invasiveness risk is analyzed based on changes in the intensity of the fluorescence signal in the surrounding area and the matrix remodeling index. This invention provides a more direct and rapid assessment of tumor cell invasiveness by observing the matrix remodeling characteristics induced during cell invasion in real time in vitro, providing a risk level reference for tumor malignancy.

The application belongs to the technical field of biomedicine, and specifically discloses a gene marker of melanoma and application thereof. The gene marker is a PDP1 gene, and the application proves the correlation between the PDP1 gene and melanoma. The expression amount of the PDP1 gene in melanoma cells is significantly higher than that in normal melanocytes. The PDP1 expression is positively correlated with the pathological stage and the lymph node metastasis condition N value. The PDP1 gene influences the cell proliferation, cell apoptosis, cell migration and cell invasion of melanocytes. Therefore, the PDP1 gene can be used as a potential target for diagnosing and treating melanoma. By detecting the mRNA or protein expression level of the PDP1 gene, melanoma can be detected, and the application has good application value.

The invention provides a wireless wearable electrical stimulation microsystem for cell infection research, and relates to the technical field of medical instruments. The system comprises a power supply module, a microprocessor module, a signal adjusting module, a wireless operation module, a load module and a signal monitoring module, the power supply module is connected with the signal adjusting module, and the power supply module supplies power to the wireless wearable electrical stimulation microsystem; the first output end of the microprocessor module is connected with the input end of the wireless operation module, the output end of the wireless operation module is connected with the first input end of the microprocessor module, and the second output end of the microprocessor module is connected with the second input end of the signal adjusting module. The output end of the signal adjusting module is connected with the input end of the load module. The output end of the load module is connected with the input end of the signal monitoring module. According to the invention, adjustable electrical stimulation signals can be provided for the electrode according to clinical requirements, the electrical stimulation process can be monitored in real time, and the safety and reliability of operation are ensured.

The invention provides a degradation agent targeting EGFRC797S as well as preparation and application thereof, and belongs to the technical field of medicines. The compound as shown in the formula I is prepared, the compound can degrade EGFR in a targeted mode, and expression of EGFR in H1975-M3 cells is remarkably reduced. The compound disclosed by the invention has obvious anti-proliferative activity on a non-small cell lung cancer cell line, particularly has good selectivity on an EGFRL858R / T790M / C797S mutant type H1975-M3 cell and an EGFRL858R / T790M mutant type NCI-H1975 cell, and is obvious in inhibition effect, and the compound disclosed by the invention is low in toxicity on normal cells. Meanwhile, the compound can obviously retard the cell cycle, promote cell apoptosis and inhibit cell invasion and migration. The compound provided by the invention can be used as an EGFRC797S degradation agent to be applied to preparation of non-small cell lung cancer cell resisting drugs. Formula I

The present invention belongs to the field of biomedicine technology and discloses a drug that inhibits colorectal cancer metastasis by targeting glucocorticoid receptor GR. The drug that inhibits colorectal cancer metastasis by targeting glucocorticoid receptor GR is 0.1 μM glucocorticoid and / or 0.1 μM belinostat. The present invention verifies the actual effect of small molecule drugs in CRC by in vitro cell invasion experiments and transcriptome sequencing analysis methods, and the effect of combined treatment with glucocorticoid and belinostat on the invasion of CRC cell line HCT116 cells; HCT116 cells are treated with 0.1 μM glucocorticoid and / or 0.1 μM belinostat for 48 hours, stained with 0.1% crystal violet and photographed, eluted with 33% acetic acid, and the absorbance value is detected by a microplate reader at 590 nm. The experimental results of the present invention show that GC promotes CRC cell invasion, and belinostat combined treatment can effectively inhibit the invasive effect caused by GC.

The application discloses a use of a DDX51 gene in human melanoma and related products. The application takes the DDX51 gene as a template, designs an RNA interference target sequence, and constructs a target gene RNA interference lentivirus vector. RT-PCR detection of the expression of the target gene in target cells, lentivirus infection of the target cells, qPCR detection of the mRNA level DDX51 gene knockdown efficiency, Celigo detection of the influence of the DDX51 gene knockdown on cell proliferation, detection of the influence of the DDX51 gene knockdown on clone formation, Invasion (Transwell with ECM) detection of the influence of the DDX51 gene knockdown on the cell invasion ability, and the like confirm that the interference target gene DDX51 has the effects of inhibiting the proliferation, clone formation, invasion and metastasis of human melanoma cells A375.

The invention relates to an application of a testicular hormone orphan nucleus receptor 4 (TR4) in non-small cell lung cancer distant metastasis. The TR4 is highly expressed in NSCLC tissues and is closely related to lymph node metastasis, TNM staging and poor prognosis. In-vitro experiments and animal models prove that up-regulation of the TR4 can enhance cell invasion and migration ability, and inhibition of the TR4 can significantly reduce the metastasis potential. The invention further provides a kit and a determination method for predicting or diagnosing the NSCLC remote metastasis based on the TR4. The ratio of the TR4 expression quantity of a detection sample to the TR4 expression quantity of a control sample is adopted as a risk assessment index; meanwhile, the invention provides application of the TR4 inhibitor in preparation of a pharmaceutical composition for inhibiting NSCLC invasion or metastasis. According to the invention, a complete technical path of'detection-layering-intervention 'is constructed, early prompt of NSCLC transfer risk can be realized, and a new molecular target is provided for individualized treatment and drug research and development.

The invention discloses a method for preventing HER2 positive breast cancer trastuzumab drug resistance through a peroxynitroso ion donor SIN-1, and relates to the technical field of biological medicine. The method comprises cell culture and drug treatment, a western blot experiment, an immunoprecipitation experiment, a scratch experiment, a cell invasion and migration experiment, a clone formation experiment, immunohistochemical staining, an immunofluorescence experiment, active oxygen and nitric oxide detection, a CCK-8 experiment, mass spectrometry, site-specific mutagenesis and cell transfection, and a nude mouse transplantation tumor experiment. The trastuzumab can reduce the level of nitric oxide and active oxygen in HER2 positive breast cancer cells, relieve nitrosation stress of the cells and inhibit nitration modification of the HER2 protein Y163 site so as to cause acquired drug resistance of tumors, and the tumor drug resistance can be effectively prevented by enhancing HER2 nitration modification through SIN-1.

Proposed are antibodies specifically binding to PTK7 and a use thereof and, more particularly, PTK7 neutralizing antibodies specifically binding to PTK7 to inhibit PTK function, and a use thereof for inhibiting angiogenesis, cell growth, cell migration, and cell invasion. The human PTK7 neutralizing monoclonal antibodies have been found to independently exhibit an effective inhibitory effect on cancer cell growth, migration, invasion in esophageal squamous cell carcinoma and triple-negative breast cancer, and angiogenesis. Therefore, the human PTK7 neutralizing monoclonal antibodies can be applied to various PTK7-positive carcinomas and angiogenic diseases, and can be further developed as a targeted drug therapy for intractable cancers and angiogenic diseases to be used as a core global treatment drug for the same.